Focus is on developing a novel platform for multiple analyte detection.

Molecular diagnostics firm Biocartis raised €10 million (about $14.94 million) in a Series A equity financing round with a syndicate of life science investors. The primary fields of applications being targeted are analysis of bio-molecules associated with risk factors, early detection, staging, treatment selection, and disease monitoring.

Based in Lausannes, Switzerland, Biocartis was founded in 2007 to develop a novel molecular diagnostics technology for low-to-highly multiplexed bioanalyte detection. The firm claims that starting from a single, low-volume clinical sample, the platform has the potential to carry out the multiplexed detection and quantification of a large variety of biological molecules including DNA, RNA, proteins, and small molecules.

The fundraising was led by Amsterdam-based Aescap Venture. Other members of the syndicate are Biovest, KBC Private Equity, Advent Venture Partners, and existing shareholder Benaruca.

Previous articleRoche Gains Access to Cerep’s Pharmacology and ADME Database
Next articleClemson University Obtains $9.3M for Tissue Regeneration Center